The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, re-checked the generic exenatide label, added the Drugs@FDA approval records and the EXSCEL outcomes trial, and added FDA’s November 13, 2026 determination that Byetta was not withdrawn from sale for safety or effectiveness reasons. 126
What this version reported
Randomized trials described in the label show lower HbA1c than placebo. A large outcomes trial of a longer-acting exenatide product did not show a reduction in cardiovascular events. In November 2026 FDA determined that Byetta was not withdrawn from sale for safety or effectiveness reasons.↗↗↗
Reader guide in this version
Key takeaway
Exenatide is a GLP-1 receptor agonist, a peptide whose amino acid sequence partly overlaps human GLP-1. It was first approved in the United States as Byetta in 2005.1,2 It is FDA-approved, with diet and exercise, to improve blood-sugar control in adults with type 2 diabetes. Drugs@FDA also lists Bydureon, Bydureon BCise and a generic exenatide application.1,3,4,5 A large outcomes trial of a longer-acting exenatide product in 14,752 adults found that it did not increase major cardiovascular events but did not show that it reduced them.7 On November 13, 2026, FDA published its determination that Byetta was not withdrawn from sale for reasons of safety or effectiveness.6
At a glance
- What it is
- A GLP-1 receptor agonist. The label states that its amino acid sequence partly overlaps that of human GLP-1.1
- FDA status
- FDA-approved. Drugs@FDA lists Byetta (first approved April 28, 2005), Bydureon (January 27, 2012), Bydureon BCise (October 20, 2017) and a generic application (November 19, 2024). The cited generic label has no boxed warning.1,2,3,4,5
- Human evidence
- Randomized, placebo-controlled blood-sugar trials described in the label and a large cardiovascular outcomes trial of a longer-acting exenatide product.1,7
- Evidence strength
- Large randomized human trials
What is exenatide?
Exenatide is a peptide that acts like GLP-1, a hormone released by the gut. The label states that its amino acid sequence partly overlaps that of human GLP-1.1
Drugs@FDA lists it as the active ingredient of Byetta, Bydureon and Bydureon BCise, and of a generic exenatide application approved on November 19, 2024. The label cited on this page is a generic exenatide label.1,2,3,4,5
How does exenatide work?
The label states that exenatide binds to and activates the GLP-1 receptor, increasing insulin release from the pancreas when blood sugar is high.1
The label also states that it suppresses inappropriately high glucagon release and slows stomach emptying, lowering blood sugar both when fasting and after meals.1
What do human studies show?
The label describes randomized, placebo-controlled trials in adults with type 2 diabetes, including a 24-week trial of 232 adults and three 30-week trials that together randomized 1,446 adults. Exenatide lowered HbA1c, a measure of long-term blood sugar, more than placebo.1
In EXSCEL, 14,752 adults with type 2 diabetes, 73.1% of whom had previous cardiovascular disease, were randomized to a longer-acting exenatide product or placebo. The main cardiovascular outcome occurred in 11.4% and 12.2% of the groups, a result that met the trial’s safety criterion but not its criterion for showing benefit.7
What the evidence base contains
- Large randomized human trial EXSCEL: a randomized, placebo-controlled cardiovascular outcomes trial of a longer-acting exenatide product in 14,752 adults with type 2 diabetes, followed for a median of 3.2 years.7
- Large randomized human trial Three 30-week randomized, double-blind, placebo-controlled trials described in the label, which together randomized 1,446 adults whose type 2 diabetes was not controlled by metformin, a sulfonylurea or both.1
- Controlled human trial A 24-week randomized, double-blind, placebo-controlled trial in 232 adults with type 2 diabetes in which exenatide was the only diabetes medicine.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Is exenatide FDA-approved?
Yes. Drugs@FDA lists Byetta, application NDA021773, with an original approval date of April 28, 2005; Bydureon (NDA022200) on January 27, 2012; Bydureon BCise (NDA209210) on October 20, 2017; and a generic exenatide application (ANDA206697) on November 19, 2024.2,3,4,5
The generic exenatide label cited here (DailyMed SPL version 17, published June 30, 2026) states that it is indicated as an adjunct to diet and exercise to improve blood-sugar control in adults with type 2 diabetes.1
That label has no boxed warning. It states that exenatide is contraindicated in people with a prior severe allergic reaction to it or a history of drug-induced immune thrombocytopenia from exenatide products, a loss of blood platelets that can cause serious or fatal bleeding.1
Its other warnings cover acute pancreatitis, low blood sugar when combined with insulin or insulin secretagogues, kidney injury from fluid loss, severe gastrointestinal reactions, antibodies to exenatide, allergic reactions, gallbladder disease and aspiration during anesthesia or deep sedation.1
On November 13, 2026, FDA published a Federal Register notice listing Byetta among drug products that are no longer marketed and determining that it was not withdrawn from sale for reasons of safety or effectiveness.6
Timeline
- FDA approves Byetta, the first exenatide product, according to Drugs@FDA.2
- FDA approves Bydureon, according to Drugs@FDA.3
- Results of the EXSCEL cardiovascular outcomes trial are published.7
- FDA approves Bydureon BCise, according to Drugs@FDA.4
- FDA approves a generic exenatide application, according to Drugs@FDA.5
- DailyMed publishes the generic exenatide label version cited on this page.1
- FDA publishes its determination that Byetta was not withdrawn from sale for reasons of safety or effectiveness.6
What is still unknown?
Whether exenatide reduces cardiovascular events: EXSCEL did not meet its criterion for showing benefit.7
How the labels for other exenatide products differ: this page cites one generic label, and the EXSCEL trial studied a longer-acting product.1,7
Its effects in people without type 2 diabetes: the label covers adults with type 2 diabetes only.1
Sources for this version
- 1Exenatide injection · SPL version 17 · published 2026-06-30 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026
- 2Drugs@FDA application NDA021773 · original submission status AP · 2005-04-28 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 3Drugs@FDA application NDA022200 · original submission status AP · 2012-01-27 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Drugs@FDA application NDA209210 · original submission status AP · 2017-10-20 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Drugs@FDA application ANDA206697 · original submission status AP · 2024-11-19 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Federal Register notice 2026-23141 · published 2026-11-13 · Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness ↗
Federal Register via GovInfo · Official source · Source checked November 14, 2026
- 7Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL, 2017) · PMID 28910237 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026